AN2 Therapeutics financials
$5.09+1.60%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$8.9M | -$10.6M | -$9.3M | -$10.0M | -$7.2M | -$11.5M | -$8.6M | -$14.0M | -$15.9M | -$18.3M | -$18.8M | -$18.2M |
| Net income | -$8.2M | -$10.0M | -$8.7M | -$9.4M | -$6.5M | -$10.6M | -$7.5M | -$12.7M | -$14.4M | -$16.6M | -$16.9M | -$16.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.18 | $-0.29 | $-0.29 | $-0.31 | $-0.21 | $-0.35 | $-0.25 | $-0.43 | $-0.48 | $-0.56 | $-0.57 | $-0.65 |
| EBITDA | -$8.9M | -$10.6M | -$9.3M | -$10.0M | -$7.2M | -$11.5M | -$8.6M | -$11.8M | -$15.9M | -$18.3M | -$18.8M | -$18.2M |
| Operating cash flow | -$7.0M | -$12.1M | -$5.2M | -$6.4M | -$7.6M | -$10.6M | -$5.3M | -$12.0M | -$14.4M | -$17.6M | -$17.1M | -$11.8M |
| Free cash flow | -$7.0M | -$12.1M | -$5.2M | -$6.4M | -$7.6M | -$10.6M | -$5.3M | -$12.0M | -$14.4M | -$17.6M | -$17.1M | -$11.8M |
| Diluted shares | 44.8M | 34.1M | 30.4M | 30.3M | 30.2M | 30.1M | 29.9M | 29.8M | 29.8M | 29.8M | 29.9M | 25.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.3M | $53.5M | $19.9M | $18.0M | $18.2M | $20.0M |
| Short-term investments | $34.1M | $31.8M | $38.1M | $43.9M | $44.7M | $47.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $81.7M | $87.5M | $62.0M | $67.2M | $75.8M | $81.3M |
| Total liabilities | $5.8M | $5.7M | $8.9M | $6.9M | $7.0M | $8.0M |
| Shareholders' equity | $75.9M | $81.8M | $53.1M | $60.4M | $68.8M | $73.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology